ASP Isotopes (NASDAQ:ASPI) Releases Earnings Results, Beats Estimates By $0.06 EPS

ASP Isotopes (NASDAQ:ASPI) issued its quarterly earnings results on Wednesday. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.06, Zacks reports. The company had revenue of $8.36 million for the quarter, compared to analysts’ expectations of $3.68 million. ASP Isotopes had a negative return on equity of 112.46% and a negative net margin of 644.40%.

ASP Isotopes Stock Performance

NASDAQ:ASPI opened at $5.55 on Tuesday. ASP Isotopes has a twelve month low of $3.92 and a twelve month high of $14.49. The company has a quick ratio of 12.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.69. The stock’s 50-day simple moving average is $5.06 and its 200 day simple moving average is $5.91. The firm has a market capitalization of $698.75 million, a PE ratio of -2.67 and a beta of 3.26.

Wall Street Analysts Forecast Growth

ASPI has been the subject of several analyst reports. Canaccord Genuity Group restated a “buy” rating and issued a $11.00 target price on shares of ASP Isotopes in a research report on Tuesday, April 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of ASP Isotopes in a research report on Friday, March 27th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $13.00.

Insider Transactions at ASP Isotopes

In related news, COO Robert Ainscow sold 25,000 shares of the company’s stock in a transaction that occurred on Friday, March 6th. The shares were sold at an average price of $4.51, for a total transaction of $112,750.00. Following the completion of the transaction, the chief operating officer directly owned 1,512,817 shares in the company, valued at $6,822,804.67. This represents a 1.63% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Heather Kiessling sold 23,124 shares of the company’s stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $5.48, for a total transaction of $126,719.52. Following the transaction, the chief financial officer owned 709,376 shares of the company’s stock, valued at $3,887,380.48. This trade represents a 3.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 90,704 shares of company stock valued at $463,252. 14.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On ASP Isotopes

Institutional investors and hedge funds have recently bought and sold shares of the company. Quantbot Technologies LP bought a new position in ASP Isotopes in the third quarter valued at about $34,000. BNP Paribas Financial Markets grew its position in shares of ASP Isotopes by 84.9% in the 2nd quarter. BNP Paribas Financial Markets now owns 5,549 shares of the company’s stock valued at $41,000 after buying an additional 2,548 shares during the last quarter. Guggenheim Capital LLC acquired a new stake in ASP Isotopes during the 4th quarter valued at approximately $72,000. Caption Management LLC increased its position in ASP Isotopes by 110.5% during the 4th quarter. Caption Management LLC now owns 13,800 shares of the company’s stock valued at $74,000 after purchasing an additional 145,800 shares during the period. Finally, Steward Partners Investment Advisory LLC bought a new position in ASP Isotopes during the 4th quarter worth approximately $74,000. Institutional investors and hedge funds own 16.80% of the company’s stock.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.